share_log

Brian Blaser Buys Handful Of Shares In QuidelOrtho

Brian Blaser Buys Handful Of Shares In QuidelOrtho

布賴恩·布拉澤購買了窺得兒醫藥的一小部分股票
Simply Wall St ·  12/15 21:19

Investors who take an interest in QuidelOrtho Corporation (NASDAQ:QDEL) should definitely note that the President, Brian Blaser, recently paid US$41.42 per share to buy US$250k worth of the stock. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.

對窺得兒醫藥公司(納斯達克:QDEL)感興趣的投資者應該特別注意,總裁布萊恩·佈雷澤(Brian Blaser)最近以每股41.42美元的價格購買了價值25萬美元的股票。 然而,這僅僅增加了少量的參股金融,而且在絕對值上也不是一筆巨大的購買。

The Last 12 Months Of Insider Transactions At QuidelOrtho

窺得兒醫藥過去12個月的內部交易

Notably, that recent purchase by Brian Blaser is the biggest insider purchase of QuidelOrtho shares that we've seen in the last year. That means that even when the share price was higher than US$41.35 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

值得注意的是,布萊恩·佈雷澤最近的購買是我們在過去一年中看到的窺得兒醫藥內部人士最大的一次股票購買。這意味着即使在股價高於41.35美元(最近價格)時,內部人士也想購買股票。他們很可能對這筆購買感到後悔,但更有可能是對公司看好。我們始終仔細關注內部人士購買股票時支付的價格。一般來說,當內部人士在高於當前價格的情況下購買股票時,會引起我們的注意,因爲這表明他們認爲股票值得在更高的價格時購買。

In the last twelve months QuidelOrtho insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

在過去的十二個月中,窺得兒醫藥的內部人士在購買股票,但沒有出售。您可以在下面查看過去12個月內部交易的可視化圖示。通過點擊下面的圖表,您可以查看每個內部交易的具體細節!

big
NasdaqGS:QDEL Insider Trading Volume December 15th 2024
納斯達克GS:QDEL 內部交易成交量 2024年12月15日

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

還有很多其他公司內部人士正在買入股票。你可能不想錯過這份內部人士正在購買的被低估的小盤公司的免費名單。

Does QuidelOrtho Boast High Insider Ownership?

窺得兒醫藥是否擁有高內部所有權?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that QuidelOrtho insiders own 5.5% of the company, worth about US$154m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

查看公司內部股東的總持股情況,可以幫助你了解他們是否與普通股東保持一致。 高比例的內部持股通常使公司領導層更加關注股東的利益。 很高興看到窺得兒醫藥的內部人士擁有5.5%的股份,價值約爲15400萬美元。 我喜歡看到這樣的內部持股比例,因爲這增加了管理層考慮股東最佳利益的可能性。

What Might The Insider Transactions At QuidelOrtho Tell Us?

內部交易在窺得兒醫藥可能告訴我們什麼?

The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest QuidelOrtho insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 1 warning sign for QuidelOrtho you should be aware of.

最近的內部購買讓人振奮。 長期的內部交易也給予我們信心。 但另一方面,公司在過去一年中出現了虧損,這讓我們感到有些謹慎。 綜合考慮顯著的內部持股,這些因素表明窺得兒醫藥的內部人士與公司目標高度一致,並且很可能認爲股價過低。 至少值得加入自選。 因此,這些內部交易可以幫助我們構建關於這隻股票的理論,但同樣了解公司面臨的風險也是值得的。 例如:我們發現了一個你應該了解的窺得兒醫藥的警示信號。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,您也可能會在其他地方找到一個絕佳的投資。請查看這個免費的有趣公司名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

在本文中,內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論